ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 24.04 |
| Open | 24.00 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 2200 |
| Day's Range | 23.69 - 24.66 |
| 52 Week Range | 12.77 - 28.67 |
| Volume | 928,720 |
| Avg. Volume | 1,402,493 |
| Market Cap | 3.518B |
| Beta (3Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | May 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.09 |
- Business Wire•19 hours ago
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months.
- Zacks•2 days ago
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•7 days ago
Should ACADIA Pharmaceuticals (NASDAQ:ACAD) Be Disappointed With Their -30% Profit?
While it may not be enough for some shareholders, we think it is good to see the ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) share price up 12% in a single quarter. But that doesn't change the fact that the returns over the last...
- Business Wire•9 days ago
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter ended March 31, 2019 on Wednesday, May 1, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, May 1, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 6759227).
- Business Wire•15 days ago
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
ACADIA is committed to supporting the Parkinson’s community and increasing awareness about Parkinson’s disease (PD) and Parkinson’s disease psychosis (PDP), a progressive and debilitating non-motor condition characterized by hallucinations and delusions related to PD. “We are driven to improve the lives of people with Parkinson’s disease psychosis and their caregivers,” said Steve Davis, ACADIA’s Chief Executive Officer.
- Markit•17 days ago
See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $2.50 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•24 days ago
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m.
- Business Wire•25 days ago
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer.
- GlobeNewswire•28 days ago
Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•29 days ago
The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 27) Baxter International Inc (NYSE: BAX ) Catalyst Pharmaceuticals ...
- Business Wire•29 days ago
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
ACADIA Pharmaceuticals Inc. (ACAD), Neuren Pharmaceuticals Limited (NEU.AX), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted by Neuren, which evaluated the safety and efficacy of trofinetide in females with Rett syndrome (RTT), have been published in Neurology®, the medical journal of the American Academy of Neurology.
- CNW Group•last month
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
- Simply Wall St.•last month
Is ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) Liquidity Good Enough?
Mid-caps stocks, like ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a market capitalization of US$3.8b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT
Q4 2018 ACADIA Pharmaceuticals Inc Earnings Call
- Motley Fool•2 months ago
Why Acadia Pharmaceuticals Stock Perked Up in February
The company's comeback story continued to gain momentum last month.
- Business Wire•2 months ago
ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at 11:20 a.m.
- TheStreet.com•2 months ago
3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks
Fourth-quarter earnings season is winding down. It disclosed encouraging Phase 2 data for Nuplazid to treat major depressive disorder in October and will start two Phase 3 studies for that indication later this year.
Motley Fool•2 months agoAcadia Pharmaceuticals Inc (ACAD) Q4 2018 Earnings Conference Call Transcript
ACAD earnings call for the period ending December 31, 2018.
- Business Wire•2 months ago
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17
- Business Wire•2 months ago
ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m.
- Zacks•2 months ago
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
- Zacks•2 months ago
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Yahoo Finance Video•2 months ago
Big Pharma faces the Senate in drug price hearings
Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.
